Marker Therapeutics - Product Candidates
Product Candidates
Pipeline
Title 1Title 1
Title 2Title 2
PreclinicalPre
Phase IPh I
Phase IIPh II
Phase IIIPh III
Patient Specific
Allo
Acute Myeloid Leukemia - MT-401
Acute Myeloid Leukemia - MT-401
Auto
Lymphoma - MT-601
Lymphoma - MT-601
2022 IND
Pancreatic Cancer - MT-601
Pancreatic Cancer - MT-601
2022 IND
OTF
Off-the-shelf
Acute Myeloid Leukemia - MT-401-OTS
Acute Myeloid Leukemia - MT-401-OTS
1st patient 2023
Lymphoma - MT-401-OTS
Lymphoma - MT-401-OTS
Ovarian Cancer - MT-401-OTS
Ovarian Cancer - MT-401-OTS
Other
Other-sub
MT-1201 (12 antigens)
MT-1201 (12 antigens)
MT-401 Combination Therapies
MT-401 Combination Therapies
MT-601 Combination Therapies:
peptide vaccine
MT-601 Combination Therapies:
peptide vaccine

Solid Tumors Hematologic malignancy